Grilled Cheese

ExploreLog inSign up
Terms of UsePrivacy PolicyCommunity StandardsHelpGet the app

Grilled Cheese is a product of Village Compute

Version devBuilt at: 2026-10-10 01:38:52 EDT

Explore

PostsPeople
LatestRanked
@plosbiology.orgOct 9, 2026, 12:05 PM

Researchers often select antibodies based on previous use or peer recommendations. This study shows that poor #antibody validation contributes to substantial avoidable consumption of animal and human biological samples, proposing interventions to improve #reliability.
🧪 #AcademicSky
plos.io/4s1Ccxl

Self-reported antibody validation practices among researchers. Distribution of IWGAV pillar usage among survey respondents (n = 107). Of 107 respondents, 77 (72.0%) used at least one IWGAV-aligned validation strategy, while 30 (28.0%) used no IWGAV pillars, relying instead on technical controls only (n = 26) or performing no validation (n = 4). Among IWGAV users, 44 used a single pillar, 22 used two pillars, 10 used three pillars, and 1 used five pillars.
@plosbiology.orgOct 8, 2026, 8:05 AM

Researchers often select antibodies based on previous use or peer recommendations. This study shows that poor #antibody validation contributes to substantial avoidable consumption of animal and human biological samples, proposing interventions to improve #reliability.
🧪 #AcademicSky
plos.io/4s1Ccxl

Self-reported antibody validation practices among researchers. Distribution of IWGAV pillar usage among survey respondents (n = 107). Of 107 respondents, 77 (72.0%) used at least one IWGAV-aligned validation strategy, while 30 (28.0%) used no IWGAV pillars, relying instead on technical controls only (n = 26) or performing no validation (n = 4). Among IWGAV users, 44 used a single pillar, 22 used two pillars, 10 used three pillars, and 1 used five pillars.
@hellobio.bsky.socialOct 7, 2026, 10:27 AM

Choosing the right antibody can make a big difference to the reliability of your results, and in this new article we share 6 key things to look for in antibody validation evidence 🙌

Read here: https://ow.ly/Eszq50ZVige

#antibody #antibodies #reproducibility #lifescience #validation #lifescience

@aqlm.bsky.socialOct 6, 2026, 12:12 AM

Tip 2: Maximize your likelihood for useful information.
Do the #experiment to determine #antibody concentration or exposure time.

Tip 3: The endeavor of #science is *figuring out how* to answer the question.
Failure can't be completely avoided, though see Tip 1 to avoid total chaos.

@plosbiology.orgOct 5, 2026, 4:15 PM

Sarbecovirus spillover presents an urgent need for cross-reactive antibodies with therapeutic potential. This study uncovers the mechanisms of broad sarbecovirus cross-reactivity of three human antibodies that can inform the rational #antibody design.
🧪 #AcademicSky #virus
plos.io/4rNWkD5

V1WT_06 binds to the RBD site V epitope using the heavy chain alone. A) A closeup view of the superimposed structure of V1WT_06 bound to WIV-1 RBD on a trimeric spike (from PDB: 8WLZ). A clash with NTD of chain B is observed when V1WT_06 Fab-RBD complex is aligned onto RBD in the up conformation (chain A) in trimeric WIV-1 spike protein. Notably, the binding site is inaccessible in the RBD-down conformation. B) V1WT_06 heavy chain only interaction with WIV-1 RBD (grey). Heavy and light chains are shown with the dark and light blue ribbons, respectively. C) V1WT_06 epitope footprint overlayed with epitope footprints of other site V neutralising antibodies including S2H97, CC25.4, 5817, R1-32, and E465 patch. SARS-CoV-2 RBD (from PDB: 6m0j) is coloured based on the amino acid conservation across 87 bat sarbecoviruses.
@plosbiology.orgOct 5, 2026, 4:10 PM

How ACE2 receptor usage shapes sarbecovirus host range and antigenicity remains unclear. This study screens bat sarbecoviruses, identifying those #viruses with generalist and specialist tropism and characterizing their #antibody neutralization patterns.
🧪 #AcademicSky
plos.io/4y9KgxG

Cryo-EM structure of RhGB07 trimeric spike in a 3-RBD down state. (A) Left: CryoEM density of the trimer spike coloured by the protomer chains the density originates from. Glycans are highlighted in teal. Centre: the trimeric spike viewed from the top rendered in cartoon representation. Right: the isolated RhGB07 RBD represented as cartoon in grey with two glycans of interest shown. (B) The C-alpha trace of the RBD of RhGB07 rendered as balls-and-sticks superimposed with the RBD of SARS-CoV-1 (PDB 7DF3) and SARS-CoV-2 (PDB 5X5B). The insets show a zoomed-in view of two regions of the RBD that show the greatest changes in the position of the C-alpha of the RBD. The region containing the ins1-loop and delta4-loop coincides with putative ACE2-interacting residues based on mapping the equivalent residues of SARS-CoV-1 and SARS-CoV-2. The ACE2-interacting residues were determined by superimposing SARS-CoV-1 and RhGB07 RBD onto the SARS-CoV-2 RBD – ACE2 (PDB: 6M0J) structure and identifying interacting residues. Highlighted residues of RhGB07 show the putative interacting residues that differ in identity to SARS-CoV-2.
@pharmaphorum.bsky.socialOct 5, 2026, 9:16 AM

#CSL has licensed rights to a potentially first-in-class #anticlaudin1 #antibody developed by #AlentisTherapeutics in a #deal that could be worth up to $1.55 billion.

pharmaphorum.com/news/csl-joi...

@plosbiology.orgOct 4, 2026, 12:15 PM

Sarbecovirus spillover presents an urgent need for cross-reactive antibodies with therapeutic potential. This study uncovers the mechanisms of broad sarbecovirus cross-reactivity of three human antibodies that can inform the rational #antibody design.
🧪 #AcademicSky #virus
plos.io/4rNWkD5

V1WT_06 binds to the RBD site V epitope using the heavy chain alone. A) A closeup view of the superimposed structure of V1WT_06 bound to WIV-1 RBD on a trimeric spike (from PDB: 8WLZ). A clash with NTD of chain B is observed when V1WT_06 Fab-RBD complex is aligned onto RBD in the up conformation (chain A) in trimeric WIV-1 spike protein. Notably, the binding site is inaccessible in the RBD-down conformation. B) V1WT_06 heavy chain only interaction with WIV-1 RBD (grey). Heavy and light chains are shown with the dark and light blue ribbons, respectively. C) V1WT_06 epitope footprint overlayed with epitope footprints of other site V neutralising antibodies including S2H97, CC25.4, 5817, R1-32, and E465 patch. SARS-CoV-2 RBD (from PDB: 6m0j) is coloured based on the amino acid conservation across 87 bat sarbecoviruses.
@plosbiology.orgOct 4, 2026, 12:10 PM

How ACE2 receptor usage shapes sarbecovirus host range and antigenicity remains unclear. This study screens bat sarbecoviruses, identifying those #viruses with generalist and specialist tropism and characterizing their #antibody neutralization patterns.
🧪 #AcademicSky
plos.io/4y9KgxG

Cryo-EM structure of RhGB07 trimeric spike in a 3-RBD down state. (A) Left: CryoEM density of the trimer spike coloured by the protomer chains the density originates from. Glycans are highlighted in teal. Centre: the trimeric spike viewed from the top rendered in cartoon representation. Right: the isolated RhGB07 RBD represented as cartoon in grey with two glycans of interest shown. (B) The C-alpha trace of the RBD of RhGB07 rendered as balls-and-sticks superimposed with the RBD of SARS-CoV-1 (PDB 7DF3) and SARS-CoV-2 (PDB 5X5B). The insets show a zoomed-in view of two regions of the RBD that show the greatest changes in the position of the C-alpha of the RBD. The region containing the ins1-loop and delta4-loop coincides with putative ACE2-interacting residues based on mapping the equivalent residues of SARS-CoV-1 and SARS-CoV-2. The ACE2-interacting residues were determined by superimposing SARS-CoV-1 and RhGB07 RBD onto the SARS-CoV-2 RBD – ACE2 (PDB: 6M0J) structure and identifying interacting residues. Highlighted residues of RhGB07 show the putative interacting residues that differ in identity to SARS-CoV-2.
@plosbiology.orgOct 3, 2026, 8:15 AM

Sarbecovirus spillover presents an urgent need for cross-reactive antibodies with therapeutic potential. This study uncovers the mechanisms of broad sarbecovirus cross-reactivity of three human antibodies that can inform the rational #antibody design.
🧪 #AcademicSky #virus
plos.io/4rNWkD5

V1WT_06 binds to the RBD site V epitope using the heavy chain alone. A) A closeup view of the superimposed structure of V1WT_06 bound to WIV-1 RBD on a trimeric spike (from PDB: 8WLZ). A clash with NTD of chain B is observed when V1WT_06 Fab-RBD complex is aligned onto RBD in the up conformation (chain A) in trimeric WIV-1 spike protein. Notably, the binding site is inaccessible in the RBD-down conformation. B) V1WT_06 heavy chain only interaction with WIV-1 RBD (grey). Heavy and light chains are shown with the dark and light blue ribbons, respectively. C) V1WT_06 epitope footprint overlayed with epitope footprints of other site V neutralising antibodies including S2H97, CC25.4, 5817, R1-32, and E465 patch. SARS-CoV-2 RBD (from PDB: 6m0j) is coloured based on the amino acid conservation across 87 bat sarbecoviruses.
@plosbiology.orgOct 3, 2026, 8:10 AM

How ACE2 receptor usage shapes sarbecovirus host range and antigenicity remains unclear. This study screens bat sarbecoviruses, identifying those #viruses with generalist and specialist tropism and characterizing their #antibody neutralization patterns.
🧪 #AcademicSky
plos.io/4y9KgxG

Cryo-EM structure of RhGB07 trimeric spike in a 3-RBD down state. (A) Left: CryoEM density of the trimer spike coloured by the protomer chains the density originates from. Glycans are highlighted in teal. Centre: the trimeric spike viewed from the top rendered in cartoon representation. Right: the isolated RhGB07 RBD represented as cartoon in grey with two glycans of interest shown. (B) The C-alpha trace of the RBD of RhGB07 rendered as balls-and-sticks superimposed with the RBD of SARS-CoV-1 (PDB 7DF3) and SARS-CoV-2 (PDB 5X5B). The insets show a zoomed-in view of two regions of the RBD that show the greatest changes in the position of the C-alpha of the RBD. The region containing the ins1-loop and delta4-loop coincides with putative ACE2-interacting residues based on mapping the equivalent residues of SARS-CoV-1 and SARS-CoV-2. The ACE2-interacting residues were determined by superimposing SARS-CoV-1 and RhGB07 RBD onto the SARS-CoV-2 RBD – ACE2 (PDB: 6M0J) structure and identifying interacting residues. Highlighted residues of RhGB07 show the putative interacting residues that differ in identity to SARS-CoV-2.
@antibodytx.bsky.socialSep 30, 2026, 3:05 PM

Antibody Therapeutics (IF=4.8, Oxford University Press) ⚡ Review Highlight -CAR NK cell therapy for solid tumors: potential and challenges
doi.org/10.1093/abt/...
#mab #mabs #antibody #antibodies #antibodydiscovery #antibodytherapeutics #biologics #naturalkillercells #CAR #CARNK

@gentlem.bsky.socialSep 26, 2026, 5:10 PM

knowablemagazine.org/content/arti...
#autoimmune-encephalitis
#antibody-associated-psychosis
It is my experience & opinion that modern U.S. clinical psychiatry continues to do a disservice by being far too reluctant to medically rule out underlying conditions prior to aggressive tx w/antipsychotics.

@molneurodegenadvnc.bsky.socialSep 24, 2026, 6:53 PM

Conformation-specific anti-pathological tau #antibody raised against AD brain-derived seed-competent tau reduces tau pathology in transgenic mice

Kiran Yanamandra, Nandini Romanul, Hiral Patel...Xavier Langlois #AlzheimersDisease #immunotherapy

link.springer.com/article/10.1...

@longevitytech.bsky.socialSep 24, 2026, 1:14 PM

Phase Ib/IIa data show an experimental antibody cutting severe COPD flare-ups by up to 100% at the highest dose, a signal for aging lungs.

Link as first comment.

#longevity #geroscience #COPD #antibody #aginglungs

Illustration of human lungs with antibody symbol and text overlay.
@mdpipharma.bsky.socialSep 17, 2026, 8:24 AM

🤔 Can one #nanoparticle deliver chemo + #targeted therapy + #antibody? This study co-loads docetaxel & neratinib + trastuzumab. Superior #tumor regression in #HER2+ models—first to combine all three!

👉 www.mdpi.com/1999-4923/17...
#BreastCancer #Nanoparticles #HER2 #DrugDelivery

@bionewscentral.comSep 15, 2026, 8:28 PM

#Immunization with #nirsevimab, a long-acting #antibody, protected #infants against #RSV and sharply reduced #hospitalizations and #ICU admissions.
#RSVprevention

@schilvi.bsky.socialSep 15, 2026, 7:58 PM

Let’s do this: #injection number #fortyfive with #Ajovy, an #antibody for migraine prophylaxis 💉. Number twenty-seven after the break.

@ucsdhealthsci.bsky.socialSep 15, 2026, 3:24 PM

A new @UCSanDiego.bsky.social and San Diego VA study has found that U.S. Marines with higher natural anti-NMDAR1 #antibody levels had ~25% lower depression and 22% lower #PTSD symptoms after traumatic brain injury — a possible built-in resilience marker.

buff.ly/o60Hvfl

@sbgrid.bsky.socialSep 14, 2026, 4:03 PM

Antibodies guiding cancer immunotherapy: a publication in @cp-cancercell.bsky.social w/ contributions from Priyamvada Acharya & colleagues from @dukemedschool.bsky.social.

Read more here: buff.ly/CrOio1I

#SBGrid #Cancer #Antibody

Load more